🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2031

Annual patent cliff calendar for 2031 — US pharmaceutical patents by expiration date.

Patents
874

Quick answer

874 indexed pharmaceutical patents have expiration dates in 2031. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 8058280

    Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof

    Takeda Pharmaceutical Company Limited · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8058300

    Polycyclic antagonists of lysophosphatidic acid receptors

    AMIRA PHARMACEUTICALS, INC. · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8058248

    Foot and mouth disease virus vaccine comprising interferons

    The United States of America, as represented by the Secretary of Agriculture · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8058244

    Cyclic peptide antitumor agents

    Northwestern University · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8058237

    Stable composition of GDF-5 and method of storage

    Advanced Technologies and Regenerative Medicine, LLC · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8058025

    Methods for determining efficacy of chemotherapeutic agents

    Precision Therapeutics, Inc. · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8057810

    Peptide substance revealing an immunogeroprotective effect, pharmaceutical composition on its base and the method of its application

    Obschestvo S Ogranichennoi Otvetstvennostyu “Sia Peptides” · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8058385

    Method for preparing conjugates using polymer maleimides

    Nektar Therapeutics · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8057990

    Screening method

    Takeda Pharmaceutical Company Limited · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8057807

    Use of botulinum toxin therapy for treatment of recalcitrant voiding dysfunction

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8058063

    Method of producing region-specific neurons from human neuronal stem cells

    The Board of Regents of the University of Texas System · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8058226

    Albumin-free factor VIII formulations

    UNIVERSITY OF CONNECTICUT · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8058268

    Neuroprotective agents for the prevention and treatment of neurodegenerative diseases

    Lixte Biotechnology, Inc. · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8063014

    Self-assembly of peptide-amphiphile nanofibers under physiological conditions

    Northwestern University · Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8063250

    Crystal forms of O-desmethylvenlafaxine fumarate

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8063195

    Mutations in a toll-like receptor motif in the NS4B of classical swine fever virus strain brescia influences virulence in swine

    The United States of America, as represented by the Secretary of Agriculture · Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8063057

    Multicyclic amino acid derivatives and methods of their use

    LEXICON PHARMACEUTICALS, INC. · Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8063211

    Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8063248

    Sphingosine kinase inhibitors

    Apogee Biotechnology Corporation · Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8062643

    Use of neurotoxin therapy for treatment of urologic and related disorders

    The Regents of the University of Colorado · Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8062647

    High concentration baclofen preparations

    The Board of Regents of the University of Texas System · Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8063047

    Pyridazine compounds and methods

    Northwestern University · Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8063084

    Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels

    Xenon Pharmaceuticals Inc. · Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8062640

    High affinity human antibodies to PCSK9

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8063066

    MAPK/ERK kinase inhibitors

    Takeda Pharmaceutical Company Limited · Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8063089

    Inhibitors of nucleophosmin (NPM) and methods for inducing apoptosis

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8063209

    Phosphonyl ester conjugates as prodrugs

    The United States of America as represented by the Department of Health and Human Services (DHHS) · Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8062654

    Drug releasing biodegradable fiber for delivery of therapeutics

    The Board of Regents of the University of Texas System · Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8067030

    Controlled release composition and method of producing the same

    Takeda Pharmaceutical Company Limited · Granted Tue Nov 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8067636

    Dihydrazide compounds, preparation and uses thereof

    Bioregen Biomedical (Shanghai) Co., Ltd · Granted Tue Nov 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8067606

    Gyrase inhibitors and uses thereof

    Vertex Pharmaceuticals Incorporated · Granted Tue Nov 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8067445

    N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors

    Panmira Pharmaceuticals, LLC · Granted Tue Nov 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8067439

    Biphenyl compounds useful as muscarinic receptor antagonists

    Theravance, Inc. · Granted Tue Nov 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8067417

    Imidazo[1,2-F]pteridines useful as inhibitors of protein kinases

    Vertex Pharmaceuticals Incorporated · Granted Tue Nov 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8067505

    Method of preparing carboxylic acid functionalized polymers

    Nektar Therapeutics · Granted Tue Nov 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8067416

    Methods and compositions for the treatment of metabolic disorders

    BIOMARIN PHARMACEUTICAL INC. · Granted Tue Nov 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8067219

    Polynucleotide encoding an ATP binding cassette transporter 1 (ABC1) polypeptide

    Xenon Pharmaceuticals Inc. · Granted Tue Nov 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8067089

    Cationic microcapsule particles

    Appleton Papers Inc. · Granted Tue Nov 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8067202

    Bacterial superantigen vaccines

    The United States of America as represented by the Secretary of the Army · Granted Tue Nov 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8067237

    Scaffolds for cell transplantation

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Nov 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8067390

    Therapeutic targeting of interleukins using siRNA in neutral liposomes

    The Board of Regents of the University of Texas System · Granted Tue Nov 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8067377

    Peptide compositions for targeting adipose tissue

    The Board of Regents of the University of Texas System · Granted Tue Nov 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8067423

    Polymorphs of dasatinib isopropyl alcohol and process for preparation thereof

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8067431

    Chemically modified small molecules

    Nektar Therapeutics · Granted Tue Nov 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8067453

    Neurotrophin production/secretion promoting agent

    Takeda Pharmaceutical Company Limited · Granted Tue Nov 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8067460

    5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated Kv1.3 potassium channel

    The Regents of the University of California · Granted Tue Nov 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8067466

    Cycloalkyl-hydroxyl compounds and compositions for cholesterol management

    Esperion Therapeutics, Inc. · Granted Tue Nov 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8067473

    Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2031?

874 published patents in our USPTO index have expiration dates falling in calendar year 2031.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.